埃索美拉唑镁治疗幽门螺杆菌阳性胃十二指肠炎的临床疗效及安全性

发布时间：2018-07-31 12:16

【摘要】：目的探讨埃索美拉唑镁治疗幽门螺杆菌(HP)阳性胃十二指肠炎的临床疗效及安全性。方法 54例HP阳性胃十二指肠炎患者随机分为对照组及试验组各27例;对照组给予克拉霉素缓释片0.5 g+阿莫西林克拉维酸钾片562.5 mg+奥美拉唑肠溶片20 mg,2次/d,口服;试验组给予克拉霉素缓释片0.5 g+阿莫西林克拉维酸钾片562.5 mg+埃索美拉唑镁肠溶片20 mg,2次/d,口服。比较两组患者治疗前后血清胃蛋白酶原(PG)Ⅰ、PGⅡ、PGⅠ/PGⅡ水平、治疗有效率及安全性。结果治疗后,与对照组比较,试验组患者血清PGⅠ、PGⅡ水平较低,PGⅠ/PGⅡ水平较高,差异显著(P0.05)。试验组的治疗有效率显著高于对照组(P0.05)。两组患者不良反应发生率无明显差异(P0.05)。结论埃索美拉唑镁能显著降低HP阳性胃十二指肠炎患者血清胃PGⅠ、PGⅡ水平,提高PGⅠ/PGⅡ水平,有效根除HP。
[Abstract]:Objective to investigate the efficacy and safety of esomeprazole magnesium in the treatment of Helicobacter pylori (HP) positive gastroduodenitis. Methods Fifty-four patients with HP positive gastroduodenitis were randomly divided into control group (n = 27) and experimental group (n = 27). The control group was treated with clarithromycin sustained release tablet 0.5 g amoxicillin clavulanate potassium tablet 562.5 mg omeprazole enteric-coated tablet 20 mg / d. The experimental group was given clarithromycin sustained release tablet 0.5 g amoxicillin clavulanate potassium tablet 562.5 mg esomeprazole magnesium enteric-coated tablet 20 mg / d. The serum levels of pepsinogen (PG) 鈪，

本文编号：2155558